Compare GEHC & A Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GEHC | A |
|---|---|---|
| Founded | 1892 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Laboratory Analytical Instruments |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.8B | 39.8B |
| IPO Year | 2022 | 1999 |
| Metric | GEHC | A |
|---|---|---|
| Price | $81.10 | $118.32 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 16 |
| Target Price | $91.17 | ★ $162.31 |
| AVG Volume (30 Days) | ★ 3.2M | 2.2M |
| Earning Date | 05-06-2026 | 05-27-2026 |
| Dividend Yield | 0.17% | ★ 0.86% |
| EPS Growth | ★ 4.84 | 3.16 |
| EPS | 4.55 | ★ 4.57 |
| Revenue | ★ $20,625,000,000.00 | $4,472,000,000.00 |
| Revenue This Year | $7.15 | $8.03 |
| Revenue Next Year | $4.53 | $6.22 |
| P/E Ratio | ★ $17.68 | $25.82 |
| Revenue Growth | 4.84 | ★ 6.43 |
| 52 Week Low | $57.65 | $96.43 |
| 52 Week High | $89.77 | $160.27 |
| Indicator | GEHC | A |
|---|---|---|
| Relative Strength Index (RSI) | 45.60 | 29.17 |
| Support Level | $77.55 | $115.37 |
| Resistance Level | $85.76 | $123.79 |
| Average True Range (ATR) | 2.28 | 3.63 |
| MACD | 0.19 | -0.28 |
| Stochastic Oscillator | 48.71 | 24.28 |
GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. The company reports four major segments: imaging (45% of revenue), advanced visualization solutions (26%), patient care solutions (16%), and pharmaceutical diagnostics (13%). The company's sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 46%, 26%, 12%, and 17% respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (about one third of revenue), pharmaceutical diagnostics (about 10%-15%), and digital solutions (just over 5%).
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools, cross lab consisting of consumables and services related to life science and applied tools, and diagnostics and genomics. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.